Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. 

Merck Global Health Innovation Fund

Casdin Capital

D1 Capital Partners

Fidelity

aMoon Fund

ArrowMark Partners

Fidelity Management and Research Company

Perceptive Advisors

Redmile Group

Helicase Venture

Irving Investors

Absci

We’re excited to announce our new strategic partnership with PrecisionLife. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. By combining our unique strengths, our goal is to create better therapies for patients with diseases that have long been challenging to treat.

Read more here: https://lnkd.in/gr3Qsp8b

#AI #Biologics #DrugDiscovery #PrecisionMedicine

For our annual Unlimiter Day this past Friday, employees from around the world gathered at our HQ in Vancouver, WA to celebrate our achievements in 2023 and plan for continued success in 2024 as we work with our new collaborators like AstraZeneca, Almirall, and PrecisionLife and continue developing our pipeline of new programs like our TL1A antibody ABS-101.

Then on Saturday, we put one of our core values, “We embrace our differences”, into action as Unlimiters volunteered with STEM Like a Girl to help build STEM kits that will be used in local schools to inspire participation in the sciences.

#AI #DrugDiscovery

Please enjoy my interview with Absci CEO Sean McClain

“We're on track to put the first de novo designed antibody with generative AI in the clinic in early 2025.”

Absci, a biotech startup using “generative AI” to create novel therapeutics, is hopefully just one year away from going into the clinic with its first design. That has already pushed Big Pharma to strike larger and larger deals with the company, says founder and CEO Sean McClain.

https://lnkd.in/eG6_MP6d

Absci
Sean McClain
#Investing #biotech #drugdevelopment #AI 

We are delighted to welcome Prof Sir Mene Pangalos to our Board of Directors and as Co-Chair of our Scientific Advisory Board. Mene brings a wealth of experience from his distinguished career, most recently as EVP of BioPharmaceuticals R&D at AstraZeneca. https://lnkd.in/grVddSSN

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-6.58M -	-14.35M 118.00%	-100.96M 603.41%	-104.90M 3.91%	-110.57M 5.40%
depreciation and amortization	491K -	1.13M 130.35%	6.65M 488.33%	13.04M 95.93%	14.00M 7.38%
deferred income tax			-8.90M -	-505K 94.33%	-52K 89.70%
stock based compensation	42K -	420K 900%	10.61M 2,425.71%	12.54M 18.21%	11.42M 8.96%
change in working capital	-89K -	1.01M 1,232.58%	-3.15M 412.10%	-1.54M 51.05%	-786K 48.96%
accounts receivables	-102K -	-1.37M 1,245.10%	230K 116.76%	-148K 164.35%
inventory	102K -	1.37M 1,245.10%	-230K 116.76%	148K 164.35%
accounts payables	82K -	903K 1,001.22%	1.57M 74.31%	-533K 133.86%	-786K 47.47%
other working capital	-171K -	105K 161.40%	-4.72M 4,595.24%	-1.01M 78.67%	786K 178.05%
other non cash items	108K -	824K 662.96%	35.15M 4,165.41%	33K 99.91%	20.57M 62,224.24%
net cash provided by operating activities	-6.03M -	-10.97M 81.86%	-60.60M 452.40%	-81.34M 34.23%	-64.64M 20.54%
investments in property plant and equipment	-1.10M -	-2.18M 98.63%	-38.05M 1,644.48%	-16.18M 57.49%	-860K 94.68%
acquisitions net	9K -	10K 11.11%	-28.13M 281,400%	-8M 71.56%
purchases of investments			-1.20M -	-108.59M 8,949.17%
sales maturities of investments			1.20M -	5M 316.67%	229.90M 4,497.94%
other investing activites			-1.20M -	783K 165.25%	-147.09M 18,885.82%
net cash used for investing activites	-1.09M -	-2.17M 99.36%	-67.38M 3,003.50%	-126.98M 88.46%	81.94M 164.53%
debt repayment	-377K -	-1.59M 322.02%	-4.15M 160.65%	-7.45M 79.65%	-2.33M 68.68%
common stock issued	10.33M -	69.33M 571.45%	210.40M 203.45%	656K 99.69%	862K 31.40%
common stock repurchased
dividends paid
other financing activites	2.76M -	3.23M 17.16%	129.94M 3,923.03%	12.03M 90.74%	-3.01M 125.04%
net cash used provided by financing activities	12.71M -	70.97M 458.58%	336.19M 373.69%	5.24M 98.44%	-4.48M 185.60%
effect of forex changes on cash
net change in cash	5.58M -	57.83M 935.49%	208.22M 260.04%	-203.08M 197.53%	12.82M 106.32%
cash at beginning of period	8.29M -	13.88M 67.36%	71.71M 416.78%	279.93M 290.37%	76.84M 72.55%
cash at end of period	13.88M -	71.71M 416.78%	279.93M 290.37%	76.84M 72.55%	89.67M 16.69%
operating cash flow	-6.03M -	-10.97M 81.86%	-60.60M 452.40%	-81.34M 34.23%	-64.64M 20.54%
capital expenditure	-1.10M -	-2.18M 98.63%	-38.05M 1,644.48%	-16.18M 57.49%	-860K 94.68%
free cash flow	-7.13M -	-13.15M 84.45%	-98.64M 650.10%	-97.51M 1.15%	-65.50M 32.83%

COM:ABSCI

Absci Corporation

Last Close

2.55

22/11 21:00

Market Cap

408.23M

Beta: -

Volume Today

1.09M

Avg: -

Preview